[14C] Menaquinone-4 was administered orally once daily at a dose of 4mg/kg for ten days to female rats of different ages to determine its blood and tissue distribution with particular attention to its distribu tion in bone. Animals aged 10 and 30 months were either ovariectomized or sham-operated as a control, and young rats aged 7 weeks were used as untreated controls. Blood concentrations of radioactivity at 24h after each dose during repeated administration increased daily and approached a steady state by the seventh dose. Higher concentrations of radioactivity in blood (plasma) were observed in older animals than in the younger ones, but there was little difference between ovariectomized rats (OVX rats) and sham-operated rats (Sham rats). In tissue samples collected at 1.5 h after administration, the liver, adipose tissue, spleen and adrenals showed higher concentrations of radioactivity than the other organs and the plasma. In bone tissues, the bone marrow (BM) and cancellous tissue (CT) of the femur showed radioactivity concentrations which were higher than that in the plasma, and these increased during repeated administration. Finally, at 24 h after the last dose, the concentrations of radioactivity in bone tissues of older animals (BM, 5,807.2ng eq/g; CT, 5,264.8ng eq/g in OVX rats aged 10 months and BM, 11,479.3ng eq/g; CT, 4,023.0ng eq/g in OVX rats aged 30 months) were several times higher than those in younger animals (BM, 2,771.6ng eq/g; CT, 890.2ng eq/g in 7-week-old untreated rats). The values in OVX rats were also higher than those in Sham rats. Furthermore, micro autoradiography studies of femur sections from OVX rats indicated that [14C] Menaqui none-4 localized in cancellous tissue where bone is known to be actively remodelled. The concentrations of radioactivity in cancellous tissue and bone marrow of OVX rats aged 10 and 30 months were comparable to the pharmacologically effective concentrations of Menaquinone-4 (10-6-10-5 M) in in vitro studies on bone formation. These findings suggest that orally administered Menaquinone-4 distributes specifically into the bone 499
Summary
[14C] Menaquinone-4 was administered orally once daily at a dose of 4mg/kg for ten days to female rats of different ages to determine its blood and tissue distribution with particular attention to its distribu tion in bone. Animals aged 10 and 30 months were either ovariectomized or sham-operated as a control, and young rats aged 7 weeks were used as untreated controls. Blood concentrations of radioactivity at 24h after each dose during repeated administration increased daily and approached a steady state by the seventh dose. Higher concentrations of radioactivity in blood (plasma) were observed in older animals than in the younger ones, but there was little difference between ovariectomized rats (OVX rats) and sham-operated rats (Sham rats). In tissue samples collected at 1.5 h after administration, the liver, adipose tissue, spleen and adrenals showed higher concentrations of radioactivity than the other organs and the plasma. In bone tissues, the bone marrow (BM) and cancellous tissue (CT) of the femur showed radioactivity concentrations which were higher than that in the plasma, and these increased during repeated administration. Finally, at 24 h after the last dose, the concentrations of radioactivity in bone tissues of older animals (BM, 5,807.2ng eq/g; CT, 5,264.8ng eq/g in OVX rats aged 10 months and BM, 11,479.3ng eq/g; CT, 4,023.0ng eq/g in OVX rats aged 30 months) were several times higher than those in younger animals (BM, 2,771.6ng eq/g; CT, 890.2ng eq/g in 7-week-old untreated rats). The values in OVX rats were also higher than those in Sham rats. Furthermore, micro autoradiography studies of femur sections from OVX rats indicated that [14C] Menaqui none-4 localized in cancellous tissue where bone is known to be actively remodelled. The concentrations of radioactivity in cancellous tissue and bone marrow of OVX rats aged 10 and 30 months were comparable to the pharmacologically effective concentrations of Menaquinone-4 (10-6-10-5 M) in in vitro studies on bone formation. These findings suggest that orally administered Menaquinone-4 distributes specifically into the bone 
RESULTS

Stability of [14C]Menaquinone-4
The radiochemical purity of the labeled compound according to HPLC analysis was more than 98% at both the first and last doses, [14C]Menaquinone-4 was considered to be stable for ten days in the dosing solution.
Blood concentrations of radioactivity Figure  1 shows the blood concentrations of radioactivity at 1. clearance of Menaquinone-4 and/or its metabolites decreased as the rats aged or that the absorption of the drug from the intestine increased with increasing age. The Day 1 and Day 9 time-concentration profiles of radioactivity are shown in Figs. 2 and 3 for three animals each from the groups aged 7 weeks and 10 months, respectively. The Tmax, Cmax, and AUC values for these groups are given in Table 3 . On Day 1, the levels of radioactivity in female rats in Group I reached maximum (804.4ngEq/ml) at 1.5 to 2h after dosing then decreased slowly. The maximum levels on Day 9 (979.5ngEq/ml) were 1.2 times higher than those on Day 1, while the levels at 24h on Day 9 (160.9ngEq/ml) were 3.9 times higher than those on Day 1 (40.8ngEq/ml). AUC values, calculated by model-independent analysis, also increased by 1.7-fold during repeated administration. Similar time-concentration profiles of radioactivity were observed on Days 1 and 9 in Groups II and III.
Tissue distribution
Tissue concentrations of radioactivity at 1.5 and 24h after the final oral administration of [14C] Menaquinone-4 are shown in Tables 4 and 5, respectively. The latter table also shows the concentrations of radioactivity at 24h after the single dose to rats in Group I. These levels were generally about one-quarter of the corresponding values observed after the final dose, demonstrating a fairly high degree of accumulation during repeated administration. However an even more marked effect was apparent in adipose tissue which showed a 15-fold increase in mean concentration (from 378.2 to 5,948.0ngEq/g) and accumulation in the pancreas was also comparatively high (showing a 7-fold increase from 436.3 to 3,027.5ngEq/g). Y. SANG et al. The concentrations of radioactivity in blood, plasma, and erythrocytes of the various groups of rats are also compared in Tables 4 and 5 . The plasma levels were 6 to 16 times higher than erythrocyte levels 1.5h after administration (Table 4) but the difference in levels decreased by 24h (Table 5 ). The plasma concentrations of radioactivity at both time points tended to increase with age as in the case of the blood levels described above, but there was little difference between the OVX and Sham groups. last administration in Group I was 1,691.7ng/ml, which corresponded to 92 .8% of total radioactivity. This decreased rapidly to 3.7ng/ml (3 .4% of total radioactivi ty) at 24h. The unchanged drug levels in OVX and Sham rats in Groups II and III were 3,026.4 and 2,638.4ng/ml at 1.5h (96.9 and 86 .1% of radioactivity, respec tively) and these decreased to 5.7 and 14.8ng/ml at 24h. In Groups IV and V , the 1.5h unchanged drug concentrations were 6,584.1 and 8 ,425.7ng/ml in the OVX and Sham rats, respectively, which corresponded to 101.5 and 106 .1% of the radioactivity in plasma. These concentrations decreased to 19 .2 and 17.9ng/ml, respectively, at 24h.
Microautoradiography Figure 4 shows the autoradiograms of the sectioned femurs taken from 30 month-old OVX rats 24h after the last administration. The dark areas, which show the presence of radioactivity, are localized around the vessels in bone tissues (a) . The dark areas are also located especially in the cancellous tissue (b) in all parts of the bone. The latter finding is fully consistent with the results of tissue distribution described above, which showed that the level of radioactivity was much higher in cancellous tissue than in other parts of bone such as the metaphysis and the diaphysis (Table 5) . DISCUSSION [14C] Menaquinone-4 was administered orally once daily for ten days to rats and the blood and plasma concentration profiles, and tissue distribution of radioac tivity were investigated in OVX and Sham rats at 10 and 30 months of age and in untreated rats of 7 weeks of age.
In all groups, the blood concentrations of radioactivity increased day by day and approached a steady state after the seventh administration . Because little unchanged Menaquinone-4 was detected in the plasma 24h after the last dose , the majority of radioactivity which accumulated in the blood probably comprised metabolites of the parent compound.
Although similar time-concentration profiles of radioactivity in blood were observed in all groups during repeated dosing, older rats showed higher concentra tions of radioactivity than younger animals. A similar pattern was seen in the plasma concentrations of both radioactive and unchanged Menaquinone-4. A decreased capacity to clear Menaquinone-4 and its metabolites is one possible explanation for the higher concentrations of radioactivity in aged rats as observed in the present study. Menaquinone-4 is mainly metabolized to some short-chain acids and their conjugated forms (20), and so the activity of oxidation and/or conjugation enzymes might influence body clearance of the unchanged drug . We plan to compare the metabolic profiles of Menaquinone-4 in both young and aged rats in the future.
A recent study in dogs (18) indicated that a new soft-capsule formulation of 
